Table 1 Characteristics of the IPF cohort (N = 300)
Age, years, median (Q1, Q3) | 70 (65, 75) |
|---|---|
Male, n (%) | 223 (74.3%) |
Race, n (%) | |
 White | 281 (93.7%) |
 Black/African-American | 8 (2.7%) |
 Asian | 6 (2.0%) |
 Other | 5 (1.7%) |
Ethnicity (Hispanic or Latino), n (%) | 8 (2.7%) |
Smoking status, n (%) | |
 Past | 202 (67.3%) |
 Never | 96 (32.0%) |
 Current | 2 (0.7%) |
Diagnostic criteriaa, n (%) | |
 Definite IPF | 220 (73.3%) |
 Probable IPF | 63 (21.0%) |
 Possible IPF | 17 (5.7%) |
Emphysema on CT, n (%) | 31 (10.3%) |
Supplemental oxygen use at rest, n (%) | 59 (20.0%)b |
Pulmonary function measures, median (Q1, Q3) | |
 FEV1 (L) | 2.2 (1.8, 2.7) |
 FEV1 (% predicted) | 77.4 (68.0, 89.1) |
 FVC (L) | 2.7 (2.2, 3.2) |
 FVC (% predicted) | 69.7 (61.0, 80.2) |
 FEV1/FVC ratio | 74.1 (72.8, 89.6) |
 DLco (mL/min/kPa) | 12.0 (8.6, 14.7) |
 DLco (% predicted) | 40.6 (31.7, 49.4) |
CPI, median (Q1, Q3) | 53.5 (46.6, 60.5) |
Antifibrotic drug use, n (%) | |
 Pirfenidone | 106 (35.3%) |
 Nintedanib | 56 (18.7%) |
 Neither pirfenidone or nintedanib | 138 (46.0%) |